Retreatment of Chronic Hepatitis C Infection with Telaprevir : Turkey Experience

Area of Science:

• Hepatology
• Virology
• Pharmacology

Background:

• Genotype 1 chronic hepatitis C virus (HCV) infection is a significant global health concern.
• Previous treatment with peginterferon alfa and ribavirin often results in low sustained virologic response rates in non-responders.
• Retreatment options for patients with genotype 1 chronic HCV who did not achieve a sustained virologic response (SVR) are limited.

Purpose of the Study:

• To evaluate the efficacy and safety of triple combination therapy including telaprevir for retreatment of genotype 1 chronic HCV.
• To assess the sustained virologic response (SVR) rates in patients receiving telaprevir, peginterferon alfa-2a, and ribavirin.

Main Methods:

• A clinical study involving adult patients (≥18 years) with genotype 1 chronic HCV and no exclusion criteria.
• Treatment regimen: telaprevir (750 mg every 8 hours), peginterferon alfa-2a (180 mcg/week), and ribavirin (1000-1200 mg/day).
• Hepatitis C virus RNA (HCV-RNA) levels were monitored at multiple time points, with SVR defined as undetectable HCV-RNA at 24 weeks post-treatment.

Main Results:

• Sustained virologic response (SVR) was achieved in 74% (37/50) of patients.
• Breakthrough (BT) or early relapse occurred in 12% (6/50) of patients.
• Treatment discontinuation due to adverse events was observed in 14% (7/50) of patients.

Conclusions:

• Triple therapy incorporating telaprevir demonstrates significantly higher efficacy compared to standard peginterferon alfa and ribavirin therapy for genotype 1 chronic HCV.
• Telaprevir-based triple therapy offers a promising retreatment option for patients with genotype 1 chronic HCV who have previously failed therapy.
• Further research may explore optimizing treatment durations and managing adverse events associated with telaprevir-based regimens.